Long-term safety study of SHR-1918 for familial hypercholesterolemia
Treatments studied
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial continues to test a drug called SHR-1918, which may help lower very high cholesterol in people with a genetic condition called homozygous familial hypercholesterolemia. It looks at whether the drug remains effective and safe over a longer period of time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have already completed the earlier SHR-1918 study and had benefits from the treatment.
- You must be willing to give written permission to join this study.
- You must not have known allergies to SHR-1918 or its components.
- You must not have had cancer in the past 5 years.
- You must not have serious other medical conditions.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a one-time gene therapy to lower extremely high cholesterol in people with a rare inherited condition. It may help reduce heart attack risk in those who haven't responded to standard treatments.
This trial is a registry that collects information from people with homozygous familial hypercholesterolemia (an inherited condition causing extremely high “bad” cholesterol). It may help researchers better understand the condition and support future studies.
This study tests a new injectable medication (SYH2070) designed to lower cholesterol in people with homozygous familial hypercholesterolemia—a genetic condition that causes extremely high cholesterol levels despite treatment. The goal is to see if this drug safely reduces cholesterol better than current options.
This trial tests a new medicine, SHR-1918, for people whose bad cholesterol (LDL-C) stays high even when they take statins and another type of cholesterol-lowering drug called a PCSK9 inhibitor. It aims to see if this additional treatment can lower their cholesterol more effectively.
This trial tests an investigational medicine (SHR-1918) added to your current statin therapy to see if it helps lower your LDL ('bad') cholesterol and triglycerides more than a placebo. It may be an option if you're on a statin but still have high cholesterol.
This trial tests a new medication, SHR-1918, to lower high triglyceride levels. It may be an option for people with moderately elevated triglycerides and controlled cholesterol.
Hear when a new Homozygous Familial Hypercholesterolemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.